SUPN Supernus Pharmaceuticals Stock Forecast Period (n+7) 20 Feb 2021


Stock Forecast


As of Sat Feb 20 2021 00:00:03 GMT+0000 (Coordinated Universal Time) shares of SUPN Supernus Pharmaceuticals 1.58 percentage change in price since the previous day's close. Around 267614 of 52685000 changed hand on the market. The Stock opened at 29.17 with high and low of 28.81 and 30 respectively. The price/earnings ratio is: 12.29 and earning per share is 2.41. The stock quoted a 52 week high and low of 13.12 and 31.99 respectively.

BOSTON (AI Forecast Terminal) Sat, Feb 20, '21 AI Forecast today took the forecast actions: In the context of stock price realization of SUPN Supernus Pharmaceuticals is a decision making process between multiple investors each of which controls a subset of design variables and seeks to minimize its cost function subject to future forecast constraints. That is, investors act like players in a game; they cooperate to achieve a set of overall goals.Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines. Machine Learning based technical analysis (n+7) for SUPN Supernus Pharmaceuticals as below:
Using machine learning modified The random walk index model RWI equivalent to a model of stock market dynamics with price expectations, we analyze the reaction of investors to speculations. Analyzing those data we were able to establish the amount by which each stock felt the speculative attacks, a dampening factor which expresses the capacity of a market of absorving a shock, and also a frequency related with volatility after the speculation. Using the correlation matrices, the speculative buffer for the shares of SUPN Supernus Pharmaceuticals as below:

SUPN Supernus Pharmaceuticals Credit Rating Overview


We rerate SUPN Supernus Pharmaceuticals because of strategic positioning, operational performance, organizational effectiveness, risk and financial management, and governance. We use econometric methods for period (n+7) simulate with Ring Oscillators ANOVA. Reference code is: 1549. Beta DRL value REG 35 Rational Demand Factor LD 6177.3516. To assess an issuer's standing in the credit markets, we may look at factors such as equity, debt, and credit default swaps (CDS) trading levels, where available, relative to peers and market averages. For example, lower-than-average debt trading levels or widening rating-adjusted spreads relative to market averages may indicate decreasing market confidence about a company's prospects and ability to meet its debt maturities. As a result, the company could have increased difficulty accessing the capital markets. Credit Rating AI Process rely on primary sources of information: Sec Filings, Financial Statements, Credit Ratings, Semantic Signals. Take a look at Machine Learning section for Financial Deep Reinforcement Learning.

Oscillators are used for generating credit risk signals by using the semantic and financial signals. The value of the oscillators indicate the strength of trend. Using the correlation matrices, the risk map for SUPN Supernus Pharmaceuticals as below:
Frequently Asked QuestionsQ: What is SUPN Supernus Pharmaceuticals stock symbol?
A: SUPN Supernus Pharmaceuticals stock referred as NASDAQ:SUPN
Q: What is SUPN Supernus Pharmaceuticals stock price?
A: On share of SUPN Supernus Pharmaceuticals stock can currently be purchased for approximately 29.61
Q: Do analysts recommend investors buy shares of SUPN Supernus Pharmaceuticals ?
A: Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines. View Machine Learning based technical analysis for SUPN Supernus Pharmaceuticals at daily forecast section
Q: What is the earning per share of SUPN Supernus Pharmaceuticals ?
A: The earning per share of SUPN Supernus Pharmaceuticals is 2.41
Q: What is the market capitalization of SUPN Supernus Pharmaceuticals ?
A: The market capitalization of SUPN Supernus Pharmaceuticals is 1560002882
We work across the world

From London to San Francisco, to our home base in (Saint Helier) Jersey, we’re looking for extraordinary and creative scientists to help us drive the field forward.

Disclaimers: AC Investment Inc. currently does not act as an equities executing broker, credit rating agency or route orders containing equities securities. In our Machine Learning experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.The rating information provided is for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage as a credit rating or as a benchmark is not permitted.

301 Massachusetts Avenue Cambridge, MA 02139 667-253-1000 pr@ademcetinkaya.com